IPO Calendar

Renaissance Capital Greenwich Fund (ARCA: IPOS)

Últimas noticias sobre Renaissance Capital Greenwich Fund (ARCA:IPOS)

Renaissance Capital Greenwich Fund

Industrials

Other

Consumer Defensive

Consumer Cyclical

Real Estate

Financial Services

Technology

Energy

Basic Materials

Healthcare

The Fund seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Index. The Index, designed by IPO research firm Renaissance Capital International, LLC (the Index Provider), is a portfolio of companies that have recently completed an initial public offering (IPO) and are listed on a U.S. exchange. IPOs are a category of unseasoned equities under-represented in core equity indices. The Index is designed to capture approximately 80% of the total market capitalization of newly public companies. At each quarterly rebalance, new IPOs are added to the index and companies that have been public for three years are removed. Constituents are weighted by tradable float with individual weights capped at 10%. The Index has been constructed using a transparent and rules-based methodology. The Fund normally invests at least 80% of its total assets in securities that comprise the Index. Depositary receipts representing securities that comprise the Index may count towards compliance with the Funds 80% policy. The Fund may also invest up to 20% of its assets in certain futures, options, and swap contracts, cash and cash equivalents, as well as in common stocks not included in the Index but which will help the Fund track the Index. Convertible securities and depositary receipts not included in the Index may be used by the Fund in seeking performance that corresponds to its Index and in managing cash flows.

PT GoTo Gojek Tokopedia Tbk

Porsche Ag

Cvc Capital Partners Plc

Socionext Inc

Var Energi A/S

Zhejiang Leapmotor Technologies Ltd

Galderma Group Ag

J&T Global Express

Cvc Capital Partners

Rakuten Bank Ltd

Midea Group

SenseTime Group Inc.

Lottomatica Group Spa

Renaissance International IPO ETF

Sector ETFs

IPOs

ETFs

IPOS

El resurgimiento de OPI, impulsado por políticas y un entorno empresarial sólido, presenta oportunidades en ETF como FPX, IPO e IPOS.

El resurgimiento de las OPI en 2025: ETF clave para aprovechar el momento

Barclays analyst George Wang maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Equal-Weight and lowers the price target from $59 to $34.

News

Price Target

Analyst Ratings

SMCI

Barclays Maintains Equal-Weight on Super Micro Computer, Lowers Price Target to $34

Barclays analyst Jeffrey Bernstein maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and lowers the price target from $106 to $98.

SBUX

Barclays Maintains Overweight on Starbucks, Lowers Price Target to $98

Barclays analyst Kannan Venkateshwar maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $710 to $650.

SPOT

Barclays Maintains Overweight on Spotify Technology, Lowers Price Target to $650

Barclays analyst Terry Ma maintains SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Equal-Weight and raises the price target from $11 to $12.

SOFI

Barclays Maintains Equal-Weight on SoFi Technologies, Raises Price Target to $12

Barclays analyst Tom O'Malley maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Equal-Weight and raises the price target from $80 to $90.

Barclays Maintains Equal-Weight on Seagate Tech Hldgs, Raises Price Target to $90

Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 11.01% on an annualized basis producing an average annual return of 25.16%. Currently, Goldman Sachs Group has a market capitalization of $170.57 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $311.05 today based on a price of $546.64 for GS at the time of writing.
<h3>Goldman Sachs Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746052210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Barclays analyst Brandt Montour maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Overweight and raises the price target from $249 to $263.

Barclays Maintains Overweight on Royal Caribbean Gr, Raises Price Target to $263

Barclays analyst Tom O'Malley maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Equal-Weight and raises the price target from $60 to $70.

QRVO

Barclays Maintains Equal-Weight on Qorvo, Raises Price Target to $70

Barclays analyst Anthony Powell maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Overweight and lowers the price target from $132 to $119.

Barclays Maintains Overweight on Prologis, Lowers Price Target to $119

Barclays analyst Nicholas Campanella maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and lowers the price target from $48 to $45.

Barclays Maintains Equal-Weight on Portland Gen Electric, Lowers Price Target to $45

Barclays analyst David Anderson maintains NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) with a Underweight and lowers the price target from $13 to $11.

Barclays Maintains Underweight on NOV, Lowers Price Target to $11

Barclays analyst George Wang maintains Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) with a Overweight and lowers the price target from $108 to $92.

LOGI

Barclays Maintains Overweight on Logitech International, Lowers Price Target to $92

Barclays analyst Jack Meehan maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $240 to $250.

Laboratory Corporation Of America Holdings

Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $250

Barclays analyst Anthony Powell maintains SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) with a Equal-Weight and lowers the price target from $76 to $60.

Barclays Maintains Equal-Weight on SL Green Realty, Lowers Price Target to $60

Barclays analyst Brendan Lynch maintains Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Underweight and lowers the price target from $38 to $35.

REXR

Barclays Maintains Underweight on Rexford Industrial Realty, Lowers Price Target to $35

Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.81 by 17.28 percent. This is a 20.25 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $321.30 million which beat the analyst consensus estimate of $313.37 million by 2.53 percent. This is a 2.89 percent increase over sales of $312.27 million the same period last year.

Earnings

Earnings Beats

CNMD

CORRECTION: Conmed Q1 Adj. EPS $0.95 Beats $0.81 Estimate, Sales $321.30M Beat $313.37M Estimate

Barclays analyst Brandon Oglenski maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Equal-Weight and lowers the price target from $32 to $28.

WERN

Barclays Maintains Equal-Weight on Werner Enterprises, Lowers Price Target to $28

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 61.22 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $629.40 million which beat the analyst consensus estimate of $619.29 million by 1.63 percent. This is a 2.59 percent decrease over sales of $646.13 million the same period last year.

TDOC

CORRECTION: Teladoc Health Q1 Adj. EPS $(0.19) Beats $(0.34) Estimate, Sales $629.40M Beat $619.29M Estimate

Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) reported quarterly losses of $(0.97) per share. This is a 423.33 percent decrease over earnings of $0.30 per share from the same period last year. The company reported $10.12 million in sales this quarter. This is a 22.96 percent increase over sales of $8.23 million the same period last year.

MTEN

Mingteng International FY EPS $(0.97) Down From $0.30 YoY, Sales $10.12M Up From $8.23M YoY

Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has outperformed the market over the past 5 years by 11.78% on an annualized basis producing an average annual return of 25.92%. Currently, Welltower has a market capitalization of $98.94 billion. 
Buying $100 In WELL: If an investor had bought $100 of WELL stock 5 years ago, it would be worth $315.79 today based on a price of $152.59 for WELL at the time of writing.
<h3>Welltower's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746051310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Renaissance Capital Greenwich Fund

Noticias

Últimas noticias sobre Renaissance Capital Greenwich Fund (ARCA:IPOS)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL